HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Could Stick With Current Advice On NDI Notifications, Old Ingredient Evidence

This article was originally published in The Rose Sheet

Executive Summary

FDA has little priority, and limited resources available for finalizing its 2016 draft guidance on NDI notifications and for establishing a process that certifies dietary ingredients as being available before October 1994, says regulatory attorney Miriam Guggenheim.For both of those developments, she says, "I'm not holding my breath."

You may also be interested in...



US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector

"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB

Sharpless On FDA's Dietary Supplement Regulation Reform: It's 'Complicated'

"I look forward to beginning a productive dialogue about reshaping our oversight of these products," acting FDA Commissioner Norman Sharpless said recently about agency's public meeting on May 16. Access to meeting at CFSAN headquarters opens at 8 a.m. and irst of four sessions on questions center stated in meeting notice begins at 9 a.m. Each discussion followed by question and answer sessions and public comments scheduled for 3 p.m.

FDA's Puzzle: Measuring How DSHEA Fits For Supplement Industry Oversight

FDA says it has "only received about 1,200 NDI notifications" in 25 years under DSHEA as US VMS market has grown from around $4b and 4,000 products to more than $40bn with 80,000 or more products. In interviews on potential changes agency may attempt to bring to its regulatory oversight, attorneys noted NDI notifications are among problems for both industry and FDA.

Related Content

Topics

UsernamePublicRestriction

Register

RS121685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel